NCT02405676Active, not recruitingPhase 2/3
BNHL-2015 for Children or Adolescents in China
Treatment Regimen or Children or Adolescent With Mature B-cell NHL or B-AL in China
Source: ClinicalTrials.gov · Last updated 19 Mar 2026
Brief summary (registry, in English)
The purpose of this study is to test whether adding 4 injections of rituximab and increasing the intensity of chemotherapy regimens in advanced patients can improve the EFS compared with the historical study CCCG-NHL-2010.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 26 Feb 2015
- Start date
- 1 Jan 2015
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Children's Cancer Group, China
- Diseases
- Childhood cancers
- NCT number
- NCT02405676
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 200
- From 1 Jan 2015 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior exposure to rituximab.
Other illness
- Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology.
- -Evidence of pregnancy or lactation period.
- Past or current anti-cancer treatment except corticosteroids during less than one week.
- Hepatitis B carrier status history of HBV or positive serology.
Other
- Follicular lymphoma, MALT and nodular marginal zone are not included into this therapeutic study
- Tumor cell negative for CD20.
Who the study is looking for
- Histology or cytologically confirmed matureB-cell NHL/AL(Burkitt, DLBCL, PMLBL,or aggressive mature B-cell NHL non other specified or specifiable)
- Able to comply with scheduled follow-up and with management of toxicity
- Signed informed consent
Age in the registry: - to 16 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| West China Second University Hospital of Sichuan University Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.